The Huntington's disease (HD) community was cheered this month by FDA approval of Austedo (deutetrabenazine), the deuterated tetrabenazine analogue from Teva Pharmaceutical Industries Ltd., to treat chorea, the involuntary, random and sudden, twisting and/or writhing movements associated with HD. (See BioWorld Today, April 5, 2017.) Read More
To keep biopharmaceutical innovation churning requires mountains of cash. Companies will need to invest as much as $2.5 billion over a 10- to 15-year period in order to bring a new therapy to the marketplace, according to a 2014 study conducted by the Tufts Center for the Study of Drug Development. (See BioWorld Today, Nov. 19, 2014.) Read More
